|
|
Article: Strong data for TMC's Angiomax vs heparins.(The Medicines Co.)(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- March 20, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
USA-based drugmaker The Medicines Company has welcomed strong results on Angiomax (bivalirudin), a direct thrombin inhibitor with a naturally reversible mechanism of action, in comparison to standard anticoagulant treatment with heparins (unfractionated or low-molecular weight).
Results form the ACUITY study, which were presented as a late-breaking trial at the American College of Cardiology scientific sessiosn held in Atlanta, Georgia, showed that Angiomax monotherapy was better in terms of the net clinical outcome endpoints versus the heparins. Net outcome rates included death, myocardial infarction, ...